{'fraction_non_alphanumeric': 0.05473098330241188, 'fraction_numerical': 0.014842300556586271, 'mean_word_length': 4.801075268817204, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Quality of life of children with cerebral palsy treated with botulinum toxin: are well-being measures appropriate?

AIM
To analyze quality of life (QOL) of children with cerebral palsy (CP) treated with botulinum toxin type A (BTXA).


METHOD
Two QOL evaluation tools, translated into Portuguese, were used: Pediatric Outcomes Data Collection Instrument (PODCI) and Child's Caregiver Questionnaire (CCQ). Questionnaires were answered by caregivers on two occasions. Patients were divided into 3 groups: I--patients who had been previously treated with BTXA and who underwent a session of BTXA; II--patients who used BTXA for the first time; III--patients previously treated with BTXA but did not in this interval.


RESULTS
Sixty-eight patients were evaluated. In group I (n=26) the functional ability had improvement for all types of CP (p=0.04), and tetraplegic increased interaction/communication (p=0.02). In group II (n=14) positioning improved (p=0.02). Group III (n=28) showed no change in QOL.


CONCLUSIONS
PODCI and CCQ are able to capture outcome in children with CP.